Cancer Immunotherapy: Bridging Basic Research and Clinical Translation
Jan 24–27, 2027 | Beaver Run Conference Center, Breckenridge, CO, United States
Scientific Organizers:
Ana Carrizosa Anderson, Drew M. Pardoll, Neta Erez, and Ivan Diaz-Padilla
×
-
Jan 24–27, 2027 | Beaver Run Conference Center, Breckenridge, CO, United States
Scientific Organizers: Ana Carrizosa Anderson, Drew M. Pardoll, Neta Erez, and Ivan Diaz-Padilla
Ana Carrizosa Anderson, PhD
Harvard Medical School
Ana C. Anderson, Ph.D., is the Albert H. Coons Professor of Neurology at Harvard Medical School, Senior Scientist at Brigham and Women's Hospital, and an Institute Member of the Broad Institute of MIT and Harvard, and Core Faculty of The Gene Lay Institute of Immunology and Inflammation. Her laboratory is best known for identifying the inhibitory molecule Tim-3 as a key regulator of T cell dysfunction in cancer, a discovery that has had significant implications for cancer immunotherapy. With earlier expertise in autoimmunity, her research integrates the study of suppressed immune responses in cancer with the mechanisms of aberrant immune activation in autoimmune disease. She serves on the editorial boards of OncoImmunology and the Journal for ImmunoTherapy of Cancer.
Drew M. Pardoll
Johns Hopkins University School of Medicine
Drew Pardoll, M.D., Ph.D., is the Abeloff Professor of Oncology, Medicine, Pathology, and Molecular Biology and Genetics at Johns Hopkins University School of Medicine, and Director of the Bloomberg~Kimmel Institute for Cancer Immunotherapy. A pioneering figure in tumor immunology, his foundational discoveries include the identification of gamma-delta T cells and NKT cells and the discovery of PD-L2, a key ligand for the PD-1 immune checkpoint, which helped lay the groundwork for PD-1 pathway-targeted therapies now used across multiple cancer types. He also demonstrated that LAG-3 is a T cell checkpoint and guided the development of anti-LAG-3 antibodies. He is a Fellow of the American Association for Cancer Research and the Society for the Immunotherapy of Cancer and an elected member of the National Academy of Inventors and the National Academy of Medicine.
Neta Erez, PhD
Weizmann Institute of Science
Neta Erez, Ph.D., is a Professor in the Department of Systems Immunology at the Weizmann Institute of Science. Her research focuses on the mechanisms of cancer metastasis, particularly the earliest stages by which cancer cells establish themselves in distant organs, with the goal of finding ways to prevent metastatic disease from taking root. She has developed unique murine models to characterize organ-specific dynamics contributing to metastasis progression and response to anti-cancer therapies, with notable contributions in breast cancer and melanoma. She currently serves as President of the Israeli Society for Cancer Research, President of the Metastasis Research Society, and is the recipient of an ERC Starting Grant and the Melanoma Research Alliance Established Investigator Award, among other honors.
Ivan Diaz-Padilla, MD, PhD
Ipsen, Oncology Global Research & Development
Ivan Diaz-Padilla, M.D., Ph.D., is Senior Vice President and Global Head of Oncology Research and Development at Ipsen, where he leads the advancement of a clinical-stage pipeline across solid tumors and hematological cancers. A central component of the portfolio is represented by innovative immune therapies . Prior to Ipsen, he served as Division Head for Immuno-Oncology at GSK. Before that, Ivan worked at Merck KGaA on the development DNA-damage response inhibitors and, at Novartis, he played a leading role in the development and approval of PI3K inhibitors (alpelisib) and CDK 4/6 inhibitors (ribociclib) for the treatment of women with breast cancer. He earned his M.D. from Universidad Autónoma de Madrid and his Ph.D. in Medicine with distinction from Universidad de Sevilla. Ivan is board-certified Medical Oncologist from the Spanish Ministry of Health.
Available Formats:
Supported by:
Livestream
In Person
On Demand
***Meeting program subject to change.
Available Formats: = Livestream = In Person = On DemandMerchandise Options
Registration Options
Sunday, January 24, 2027
Fundraising
Registration
4:00–8:00 PM
Colorado Ballroom Foyer
Welcome Mixer
6:00–8:00 PM
Colorado Ballroom Foyer
Monday, January 25, 2027
Breakfast
7:00–8:00 AM
Summit Gallery
Welcome Remarks
8:00–8:10 AM
Colorado Ballroom Peak 4-5
Keynote Address
8:10–9:00 AM
Colorado Ballroom Peak 4-5
Antoni Ribas, University of California, Los Angeles
How Tumors Enable Immunotherapy
How Tumors Enable Immunotherapy
Reimagining Checkpoint Targeted Therapies
9:00–11:15 AM
Colorado Ballroom Peak 4-5
Ivan Diaz-Padilla, Ipsen, Oncology Global Research & Development
Lessons from Checkpoint Blockade Trials
Lessons from Checkpoint Blockade Trials
Andrea Cercek, Memorial Sloan Kettering Cancer Center
Neoadjuvant Checkpoint Blockade in MMRd Cancer
Neoadjuvant Checkpoint Blockade in MMRd Cancer
Drew M. Pardoll, Johns Hopkins University School of Medicine
Understanding Resistance to Checkpoint Inhibition based on Neoadjuvant Clinical Trials
Understanding Resistance to Checkpoint Inhibition based on Neoadjuvant Clinical Trials
Short Talk(s) Chosen from Abstracts
Coffee Break
9:30–9:50 AM
Colorado Ballroom Foyer
Panel Discussion: Circadian Control of Immunotherapy
11:25–12:25 PM
Colorado Ballroom Peak 4-5
Poster Setup
12:25–1:00 PM
Colorado Ballroom Peak 1-3
On Own for Lunch
12:25–2:30 PM
Poster Viewing
1:00–10:00 PM
Colorado Ballroom Peak 1-3
Symposia Spotlight 1: Cancer-Neuroimmunology
2:30–4:30 PM
Colorado Ballroom Peak 4-5
Short Talks Chosen from Abstracts
Coffee Available
4:30–5:00 PM
Colorado Ballroom Foyer
Biological Insights from Systems that Model Human Cancer
5:00–7:00 PM
Colorado Ballroom Peak 4-5
Daniela Thommen, Netherlands Cancer Institute
Rewiring T Cells in PD1 Resistant Tumors
Rewiring T Cells in PD1 Resistant Tumors
Neta Erez, Weizmann Institute of Science
Stromal and Immune Plasticity Shape the Metastatic Niche
Stromal and Immune Plasticity Shape the Metastatic Niche
Raza Ali, University of Cambridge
Systems Cancer Pathology
Systems Cancer Pathology
Short Talk(s) Chosen from Abstracts
Social Hour with Dinner
7:00–8:00 PM
Summit Gallery
Poster Session 1
7:30–10:00 PM
Colorado Ballroom Peak 1-3
Tuesday, January 26, 2027
Breakfast
7:00–8:00 AM
Summit Gallery
Harnessing Innate Cells for Cancer Therapy
8:00–11:00 AM
Colorado Ballroom Peak 4-5
Eric Vivier, Aix Marseille University and Innate Pharma
Harnessing NK Cells in Cancer Therapies
Harnessing NK Cells in Cancer Therapies
Seth B Coffelt, University of Glasgow
gamma delta T Cells as Architects of the Tumor Microenvironment
gamma delta T Cells as Architects of the Tumor Microenvironment
Judith A. Varner, University of California, San Diego
Macrophage Directed Immunotherapies
Macrophage Directed Immunotherapies
Marco Colonna, Washington University School of Medicine
Trem2 based Therapies in Cancer
Trem2 based Therapies in Cancer
Short Talk(s) Chosen from Abstracts
Coffee Break
9:00–9:20 AM
Colorado Ballroom Foyer
Poster Setup
11:00–1:00 PM
Colorado Ballroom Peak 1-3
On Own for Lunch
11:00–3:00 PM
Poster Viewing
1:00–10:00 PM
Colorado Ballroom Peak 1-3
Career Roundtable
3:00–4:30 PM
Colorado Ballroom Peak 4-5
Coffee Available
4:30–5:00 PM
Colorado Ballroom Foyer
Mechanisms Shaping T Cell Differentiation in Cancer
5:00–7:00 PM
Colorado Ballroom Peak 4-5
Mary Philip, Vanderbilt University Medical Center
Early CD8+ T Cell Fate Commitment in Cancer
Early CD8+ T Cell Fate Commitment in Cancer
Ana Carrizosa Anderson, Harvard Medical School
Transcriptional Control of CD8+ T Cell State Transitions
Transcriptional Control of CD8+ T Cell State Transitions
Jean-Christophe Beltra, University of Basel
Cytokine-Directed Gene Programs Shaping CD8+ T Cell Differentiation in Cancer
Cytokine-Directed Gene Programs Shaping CD8+ T Cell Differentiation in Cancer
Short Talk(s) Chosen from Abstracts
Social Hour with Dinner
7:00–8:00 PM
Summit Gallery
Poster Session 2
7:30–10:00 PM
Colorado Ballroom Peak 1-3
Wednesday, January 27, 2027
Breakfast
7:00–8:00 AM
Summit Gallery
Applying Engineering and Materials Science to Cancer Immunotherapy
8:00–11:00 AM
Colorado Ballroom Peak 4-5
David J. Mooney, Harvard University
Engineering T Cell Cancer Therapies
Engineering T Cell Cancer Therapies
Jason Luke, Strand Therapeutics
Cell-Type Specific Delivery and Regulation of mRNA Therapeutics and in vivo Cell Therapy
Cell-Type Specific Delivery and Regulation of mRNA Therapeutics and in vivo Cell Therapy
Peter Benedict Kirk, Immunocore
T Cell Engagers for Solid Tumor Indications
T Cell Engagers for Solid Tumor Indications
Jamie Spangler, Johns Hopkins University
Engineering Proteins for Immunotherapy
Engineering Proteins for Immunotherapy
Short Talk(s) Chosen from Abstracts
Coffee Break
9:00–9:20 AM
Colorado Ballroom Foyer
On Own for Lunch
11:00–2:30 PM
Symposia Spotlight 2
2:30–4:30 PM
Colorado Ballroom Peak 4-5
Short Talks Chosen from Abstracts
Coffee Available
4:30–5:00 PM
Colorado Ballroom Foyer
Pushing the Envelope in Cancer Vaccines: Generation and Application
5:00–6:15 PM
Colorado Ballroom Peak 4-5
Anna Morena D'Alise, Nouscom Srl
Talk Title to be Announced
Talk Title to be Announced
Lélia Delamarre, Genentech, Inc.
Individualized Neoantigen RNA Vaccines
Individualized Neoantigen RNA Vaccines
Short Talk(s) Chosen from Abstracts
Closing Keynote Address
6:15–7:05 PM
Colorado Ballroom Peak 4-5
Yardena Samuels, Weizmann Institute of Science
Novel Mechanisms Producing Targetable Tumor Antigens
Novel Mechanisms Producing Targetable Tumor Antigens
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
7:05–7:15 PM
Colorado Ballroom Peak 4-5
Social Hour with Dinner
7:15–8:15 PM
Summit Gallery
Entertainment
8:00–9:00 PM
Cash Bar
8:00–9:00 PM
Thursday, January 28, 2027
Departure
12:00–11:59 PM
Subscribe for Updates